MarketInOut Stock Screener Log In | Sign Up

Compugen Ltd

TLV • Healthcare • Biotechnology • Quote as of 10/30/2026
Compugen Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization563.25 mln
Float94.37 mln
Earnings Date11/10/2026

EPS

1.21
Decent

P / E

4.91
Deeply undervalued

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-1.67
Likely manipulated

Relative Strength

14 / 100
Significantly lagging

Debt / Equity

0.03
Debt-free

Business Description

Compugen is an Israeli biotech company focused on discovering and developing new cancer treatments, with operations spanning the United States and Europe. Its lead drug candidates work by targeting specific proteins that help tumors evade the immune system, with several currently being tested in clinical trials for various solid tumor cancers, including an advanced study for lung cancer. The company works alongside major pharmaceutical partners, including Bristol-Myers Squibb, AstraZeneca, and Gilead Sciences, to advance its treatments through development and toward the market.

Key Fundamentals

EPS1.21
P/E4.91
ROE48.37
RPS2.43
ROIC139
ROA28.41
EBITDA, mln117
EV / EBITDA2.78
EV / EBIT2.78
Revenue, mln240
EV / Revenue1.36

Quote Details

Last 623.20
Change -7.3 (-1.16%)
Open 630.50
Volume 1,100
Turnover 685,520
Average Volume 34,296

Financial Ratios

Pre-Tax Profit Margin49
Leverage Ratio1.56
Current Ratio5.72
Price / Book2.61
Price / Tangible Book2.61
Price / Free Cash Flow6.33
Debt / Equity0.03
Price / Sales2.88

Financial Strength

Altman Z-Score0.51
Piotroski F-Score 7 / 9
Beneish M-Score-1.67
Price to Graham Number0.83

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -4.51% 29 / 100   
1 Month -14.21% 11 / 100   
2 Months -12.78% 28 / 100   
6 Months -27.07% 17 / 100   
1 Year 0.52% 49 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog